The Increase in Thyroid Cancer Incidence During the Last Four Decades is Accompanied by a High Frequency of BRAF Mutations and a Sharp Increase in RAS Mutations

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2013 Nov 20

PMID 24248188

Citations 165

Authors

Chan Kwon Jung

Mark P Little

Jay H Lubin

Alina V Brenner

Samuel A Wells Jr

Alice J Sigurdson

Yuri E Nikiforov

Affiliations

Soon will be listed here.

Abstract

Context: Thyroid cancer incidence rates in the United States and globally have increased steadily over the last 40 years, primarily due to a tripling of the incidence of papillary thyroid carcinoma (PTC).

Objective: The purpose of this study was to analyze trends in demographic, clinical, pathologic, and molecular characteristics of PTC from 1974 to 2009.

Design And Setting: We identified and histologically reviewed 469 consecutive cases of PTC from one US institution from 4 preselected periods (1974 to 1985, 1990 to 1992, 2000, and 2009) and assessed BRAF and RAS point mutations and RET/PTC rearrangements among 341 tumors ≥0.3 cm in size. Changes over time were analyzed using polytomous and binary logistic regression; all analyses were adjusted for age and sex.

Results: During this period, the median age of patients at diagnosis increased from 37 to 53 years (P < .001) and the percentage of microcarcinomas (≤1.0 cm) increased from 33% to 51% (P < .001), whereas extrathyroidal extension and advanced tumor stage decreased from 40% to 21% (P = .005) and from 43% to 28% (P = .036), respectively. Changes in tumor histopathology showed a decrease in classic PTC and an increase in the follicular variant (P < .001). The proportion of tumors with a BRAF mutation was stable (∼46%) but increased from 50% to 77% (P = .008) within classic papillary PTCs. The proportion of tumors with RAS mutations increased from 3% to 25% and within follicular pattern tumors from 18% to 44% (P < .001). The proportion of RET/PTC rearrangements decreased from 11% to 2% (P = .038).

Conclusions: Similar to US national trends, we found an increasing age at diagnosis and greater detection of smaller-sized intrathyroidal PTCs. However, the overall proportion of BRAF mutations remained stable. Sharply rising percentages of the follicular variant histology and RAS mutations after 2000 suggest new and more recent etiologic factors. The increased incidence is not likely to be due to environmental or therapeutic radiation because the percentage of RET/PTC rearrangements decreased.

Citing Articles

Genome-wide transcriptome analysis and drug target discovery reveal key genes and pathways in thyroid cancer metastasis.

Zou M, Qattan A, Al-Alwan M, Ghebeh H, Binjumah N, Al-Haj L Front Endocrinol (Lausanne). 2025; 16:1514264.

PMID: 39996058 PMC: 11847698. DOI: 10.3389/fendo.2025.1514264.

Clinicopathological Characteristics of Thyroid Cancer: A 10-Year Experience at a Tertiary Care Center in Saudi Arabia.

Alshahrani A, Alshehri S, Ajwah I, Alotay F, AlQahtani F Cureus. 2025; 16(12):e76068.

PMID: 39835020 PMC: 11743822. DOI: 10.7759/cureus.76068.

A powerful framework for differential co-expression analysis of general risk factors.

Bass A, Cutler D, Epstein M bioRxiv. 2024; .

PMID: 39677786 PMC: 11642831. DOI: 10.1101/2024.11.29.626006.

Association of radiomic features with genomic signatures in thyroid cancer: a systematic review.

Luciano N, Orlandella F, Braile M, Cavaliere C, Aiello M, Franzese M J Transl Med. 2024; 22(1):1088.

PMID: 39616372 PMC: 11608493. DOI: 10.1186/s12967-024-05896-z.

Thyroid Cancer research at endocrinology and metabolism research institute (EMRI): a report of scientific activities between 2005 and 2020.

Samimi H, Shirzad N, Sajjadi-Jazi S, Heshmat R, Amoli M, Mohajeri-Tehrani M J Diabetes Metab Disord. 2024; 23(2):1-9.

PMID: 39610531 PMC: 11599522. DOI: 10.1007/s40200-020-00702-1.

References

Mettler Jr F, Bhargavan M, Faulkner K, Gilley D, Gray J, Ibbott G . Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources--1950-2007. Radiology. 2009; 253(2):520-31. DOI: 10.1148/radiol.2532082010. View

Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V . Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst. 2005; 97(10):724-32. DOI: 10.1093/jnci/dji129. View

Nikiforov Y, Rowland J, Bove K, Fagin J . Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997; 57(9):1690-4. View

Takahashi K, Eguchi H, Arihiro K, Ito R, Koyama K, Soda M . The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol Carcinog. 2006; 46(3):242-8. DOI: 10.1002/mc.20277. View

Shu X, Perentesis J, Wen W, Buckley J, Boyle E, Ross J . Parental exposure to medications and hydrocarbons and ras mutations in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Cancer Epidemiol Biomarkers Prev. 2004; 13(7):1230-5. View

Kelley M, Littman S . Etiology of the mutational spectrum of ras genes in human carcinomas. J Natl Cancer Inst. 2002; 94(20):1516-7. DOI: 10.1093/jnci/94.20.1516. View

Romei C, Fugazzola L, Puxeddu E, Frasca F, Viola D, Muzza M . Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab. 2012; 97(9):E1758-65. DOI: 10.1210/jc.2012-1269. View

Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A . Frequent k- ras -2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer. 2001; 84(7):982-9. PMC: 2363841. DOI: 10.1054/bjoc.2000.1675. View

Colonna M, Guizard A, Schvartz C, Velten M, Raverdy N, Molinie F . A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983-2000). Eur J Cancer. 2007; 43(5):891-900. DOI: 10.1016/j.ejca.2006.11.024. View

10.

Tufano R, Teixeira G, Bishop J, Carson K, Xing M . BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore). 2012; 91(5):274-286. DOI: 10.1097/MD.0b013e31826a9c71. View

11.

Ghossein R . Encapsulated malignant follicular cell-derived thyroid tumors. Endocr Pathol. 2010; 21(4):212-8. DOI: 10.1007/s12022-010-9141-8. View

12.

Barletta E, Gorini G, Vineis P, Miligi L, Davico L, Mugnai G . Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents. Carcinogenesis. 2003; 25(5):749-55. DOI: 10.1093/carcin/bgh057. View

13.

Weihrauch M, Benick M, Lehner G, Wittekind M, Bader M, Wrbitzk R . High prevalence of K-ras-2 mutations in hepatocellular carcinomas in workers exposed to vinyl chloride. Int Arch Occup Environ Health. 2001; 74(6):405-10. DOI: 10.1007/s004200100244. View

14.

Boas M, Feldt-Rasmussen U, Main K . Thyroid effects of endocrine disrupting chemicals. Mol Cell Endocrinol. 2011; 355(2):240-8. DOI: 10.1016/j.mce.2011.09.005. View

15.

Enewold L, Zhu K, Ron E, Marrogi A, Stojadinovic A, Peoples G . Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009; 18(3):784-91. PMC: 2676561. DOI: 10.1158/1055-9965.EPI-08-0960. View

16.

Hong H, Devereux T, Melnick R, Eldridge S, Greenwell A, Haseman J . Both K-ras and H-ras protooncogene mutations are associated with Harderian gland tumorigenesis in B6C3F1 mice exposed to isoprene for 26 weeks. Carcinogenesis. 1997; 18(4):783-9. DOI: 10.1093/carcin/18.4.783. View

17.

Cramer J, Fu P, Harth K, Margevicius S, Wilhelm S . Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery. 2010; 148(6):1147-52. DOI: 10.1016/j.surg.2010.10.016. View

18.

Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P . Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009; 94(5):1612-7. DOI: 10.1210/jc.2008-2390. View

19.

Widder S, Guggisberg K, Khalil M, Pasieka J . A pathologic re-review of follicular thyroid neoplasms: the impact of changing the threshold for the diagnosis of the follicular variant of papillary thyroid carcinoma. Surgery. 2008; 144(1):80-5. DOI: 10.1016/j.surg.2007.11.014. View

20.

Nikiforova M, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf J . Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett. 2004; 209(1):1-6. DOI: 10.1016/j.canlet.2003.12.004. View